Clinical Trials · NCT03058939
Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- University of Chicago
- Enrollment
- 0
- Start date
- Nov 2018
- Locations
- 1 site, Nigeria
- Primary endpoint
- Measure overall clinical response rate (OCR)